Enovis Corporation (NYSE: ENOV) Stock Competitors & Peer Comparison
See ENOV's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ENOV and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ENOV | $27.07 | -3.56% | 1.6B | 8.01 | $3.38 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $100.68 | +1.87% | 175.3B | 19.32 | $5.21 | +2.48% |
| ISRG | $345.42 | -11.20% | 142.5B | 41.82 | $9.62 | N/A |
| SYK | $319.87 | -3.42% | 122.6B | 23.89 | $13.39 | +1.09% |
| MDT | $83.20 | -0.43% | 106.5B | 15.04 | $5.53 | +3.43% |
| BSX | $44.03 | -1.32% | 65.4B | 14.20 | $3.10 | N/A |
| EW | $85.73 | -2.40% | 49.4B | 31.75 | $2.70 | N/A |
| DXCM | $76.65 | -1.71% | 29.6B | 32.90 | $2.33 | N/A |
| RMD | $198.99 | -1.86% | 28.9B | 18.47 | $10.77 | +1.21% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
ENOV vs BSX-PA Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ENOV's ROE is -0.60%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
ENOV vs ABT Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ABT has a market cap of 175.3B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ABT trades at $100.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ABT's P/E ratio is 19.32. In terms of profitability, ENOV's ROE is -0.60%, compared to ABT's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ABT's competition here
Intuitive Surgical, Inc. (NASDAQ: ISRG)
ENOV vs ISRG Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ISRG has a market cap of 142.5B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ISRG trades at $345.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ISRG's P/E ratio is 41.82. In terms of profitability, ENOV's ROE is -0.60%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, ENOV is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ISRG's competition here
Stryker Corporation (NYSE: SYK)
ENOV vs SYK Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, SYK has a market cap of 122.6B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while SYK trades at $319.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas SYK's P/E ratio is 23.89. In terms of profitability, ENOV's ROE is -0.60%, compared to SYK's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SYK's competition here
Medtronic plc (NYSE: MDT)
ENOV vs MDT Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, MDT has a market cap of 106.5B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while MDT trades at $83.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas MDT's P/E ratio is 15.04. In terms of profitability, ENOV's ROE is -0.60%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
ENOV vs BSX Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, BSX has a market cap of 65.4B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while BSX trades at $44.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas BSX's P/E ratio is 14.20. In terms of profitability, ENOV's ROE is -0.60%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ENOV vs EW Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, EW has a market cap of 49.4B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while EW trades at $85.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas EW's P/E ratio is 31.75. In terms of profitability, ENOV's ROE is -0.60%, compared to EW's ROE of +0.11%. Regarding short-term risk, ENOV is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
ENOV vs DXCM Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, DXCM has a market cap of 29.6B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while DXCM trades at $76.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas DXCM's P/E ratio is 32.90. In terms of profitability, ENOV's ROE is -0.60%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, ENOV is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
ENOV vs RMD Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, RMD has a market cap of 28.9B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while RMD trades at $198.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas RMD's P/E ratio is 18.47. In terms of profitability, ENOV's ROE is -0.60%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ENOV is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check RMD's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
ENOV vs ZBH Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ZBH has a market cap of 17.6B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ZBH trades at $91.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ZBH's P/E ratio is 10.75. In terms of profitability, ENOV's ROE is -0.60%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ENOV is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
ENOV vs ABMD Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ENOV's ROE is -0.60%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ABMD's competition here
Smith & Nephew plc (NYSE: SNN)
ENOV vs SNN Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while SNN trades at $30.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas SNN's P/E ratio is 16.53. In terms of profitability, ENOV's ROE is -0.60%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ENOV vs ALGN Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ALGN has a market cap of 12.7B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ALGN trades at $176.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ALGN's P/E ratio is 16.11. In terms of profitability, ENOV's ROE is -0.60%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, ENOV is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ALGN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ENOV vs SWAV Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ENOV's ROE is -0.60%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ENOV is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SWAV's competition here
Penumbra, Inc. (NYSE: PEN)
ENOV vs PEN Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while PEN trades at $318.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas PEN's P/E ratio is 83.11. In terms of profitability, ENOV's ROE is -0.60%, compared to PEN's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check PEN's competition here
Insulet Corp. (NASDAQ: PODD)
ENOV vs PODD Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, PODD has a market cap of 11.4B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while PODD trades at $164.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas PODD's P/E ratio is 30.49. In terms of profitability, ENOV's ROE is -0.60%, compared to PODD's ROE of +0.21%. Regarding short-term risk, ENOV is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check PODD's competition here
Globus Medical, Inc. (NYSE: GMED)
ENOV vs GMED Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, GMED has a market cap of 10.4B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while GMED trades at $77.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas GMED's P/E ratio is 17.34. In terms of profitability, ENOV's ROE is -0.60%, compared to GMED's ROE of +0.13%. Regarding short-term risk, ENOV is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check GMED's competition here
Masimo Corporation (NASDAQ: MASI)
ENOV vs MASI Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas MASI's P/E ratio is 44.43. In terms of profitability, ENOV's ROE is -0.60%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ENOV is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check MASI's competition here
Glaukos Corporation (NYSE: GKOS)
ENOV vs GKOS Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, GKOS has a market cap of 9.2B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while GKOS trades at $156.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas GKOS's P/E ratio is -182.44. In terms of profitability, ENOV's ROE is -0.60%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, ENOV is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKR)
ENOV vs BRKR Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, BRKR has a market cap of 8.9B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while BRKR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas BRKR's P/E ratio is 31.99. In terms of profitability, ENOV's ROE is -0.60%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, ENOV is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check BRKR's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ENOV vs BIO-B Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, BIO-B has a market cap of 8.4B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while BIO-B trades at $324.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas BIO-B's P/E ratio is 96.41. In terms of profitability, ENOV's ROE is -0.60%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, ENOV is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ENOV vs BIO Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, BIO has a market cap of 8.2B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while BIO trades at $304.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas BIO's P/E ratio is 32.81. In terms of profitability, ENOV's ROE is -0.60%, compared to BIO's ROE of +0.02%. Regarding short-term risk, ENOV is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check BIO's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ENOV vs NARI Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas NARI's P/E ratio is -59.24. In terms of profitability, ENOV's ROE is -0.60%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ENOV is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
ENOV vs LIVN Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while LIVN trades at $80.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas LIVN's P/E ratio is 20.18. In terms of profitability, ENOV's ROE is -0.60%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, ENOV is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ENOV vs IRTC Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while IRTC trades at $110.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas IRTC's P/E ratio is -205.98. In terms of profitability, ENOV's ROE is -0.60%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, ENOV is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
ENOV vs AXNX Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ENOV's ROE is -0.60%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ENOV is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check AXNX's competition here
Integer Holdings Corporation (NYSE: ITGR)
ENOV vs ITGR Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ITGR has a market cap of 3.4B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ITGR trades at $95.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ITGR's P/E ratio is 15.81. In terms of profitability, ENOV's ROE is -0.60%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, ENOV is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ITGR's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ENOV vs ESTA Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ESTA has a market cap of 2.7B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ESTA trades at $92.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ESTA's P/E ratio is -64.29. In terms of profitability, ENOV's ROE is -0.60%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, ENOV is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ESTA's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ENOV vs TMDX Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, TMDX has a market cap of 2.6B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while TMDX trades at $73.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas TMDX's P/E ratio is 30.20. In terms of profitability, ENOV's ROE is -0.60%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, ENOV is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ENOV vs AXGN Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, AXGN has a market cap of 2.1B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while AXGN trades at $39.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas AXGN's P/E ratio is 104.87. In terms of profitability, ENOV's ROE is -0.60%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, ENOV is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check AXGN's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ENOV vs NUVA Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ENOV's ROE is -0.60%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ENOV is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check NUVA's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ENOV vs UFPT Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while UFPT trades at $242.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas UFPT's P/E ratio is 25.21. In terms of profitability, ENOV's ROE is -0.60%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ENOV is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check UFPT's competition here
Novocure Ltd (NASDAQ: NVCR)
ENOV vs NVCR Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while NVCR trades at $15.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas NVCR's P/E ratio is -10.41. In terms of profitability, ENOV's ROE is -0.60%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, ENOV is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check NVCR's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ENOV vs BFLY Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, BFLY has a market cap of 1.7B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while BFLY trades at $6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas BFLY's P/E ratio is -27.54. In terms of profitability, ENOV's ROE is -0.60%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, ENOV is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check BFLY's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ENOV vs IART Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, IART has a market cap of 1.5B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while IART trades at $19.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas IART's P/E ratio is 8.41. In terms of profitability, ENOV's ROE is -0.60%, compared to IART's ROE of -0.48%. Regarding short-term risk, ENOV is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check IART's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ENOV vs AHCO Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while AHCO trades at $10.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas AHCO's P/E ratio is 24.91. In terms of profitability, ENOV's ROE is -0.60%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, ENOV is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check AHCO's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ENOV vs INSP Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, INSP has a market cap of 1.5B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while INSP trades at $50.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas INSP's P/E ratio is 19.97. In terms of profitability, ENOV's ROE is -0.60%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ENOV is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check INSP's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ENOV vs ATEC Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ATEC trades at $8.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ATEC's P/E ratio is -77.59. In terms of profitability, ENOV's ROE is -0.60%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, ENOV is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ATEC's competition here
Heska Corporation (NASDAQ: HSKA)
ENOV vs HSKA Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ENOV's ROE is -0.60%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ENOV is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check HSKA's competition here
CONMED Corporation (NYSE: CNMD)
ENOV vs CNMD Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, CNMD has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while CNMD trades at $43.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas CNMD's P/E ratio is 9.51. In terms of profitability, ENOV's ROE is -0.60%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, ENOV is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check CNMD's competition here
IRadimed Corporation (NASDAQ: IRMD)
ENOV vs IRMD Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while IRMD trades at $97.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas IRMD's P/E ratio is 49.13. In terms of profitability, ENOV's ROE is -0.60%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, ENOV is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check IRMD's competition here
Artivion, Inc. (NYSE: AORT)
ENOV vs AORT Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while AORT trades at $25.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas AORT's P/E ratio is 38.51. In terms of profitability, ENOV's ROE is -0.60%, compared to AORT's ROE of +0.03%. Regarding short-term risk, ENOV is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check AORT's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ENOV vs TNDM Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while TNDM trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas TNDM's P/E ratio is -15.53. In terms of profitability, ENOV's ROE is -0.60%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, ENOV is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check TNDM's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ENOV vs AVNS Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while AVNS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas AVNS's P/E ratio is 27.76. In terms of profitability, ENOV's ROE is -0.60%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ENOV is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check AVNS's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ENOV vs SILK Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas SILK's P/E ratio is -18.96. In terms of profitability, ENOV's ROE is -0.60%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ENOV is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
ENOV vs FNA Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas FNA's P/E ratio is -19.83. In terms of profitability, ENOV's ROE is -0.60%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ENOV is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check FNA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ENOV vs PRCT Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while PRCT trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas PRCT's P/E ratio is -10.56. In terms of profitability, ENOV's ROE is -0.60%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, ENOV is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ENOV vs LMRI Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while LMRI trades at $11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas LMRI's P/E ratio is -21.67. In terms of profitability, ENOV's ROE is -0.60%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ENOV is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check LMRI's competition here
InMode Ltd. (NASDAQ: INMD)
ENOV vs INMD Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, INMD has a market cap of 896.4M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while INMD trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas INMD's P/E ratio is 10.00. In terms of profitability, ENOV's ROE is -0.60%, compared to INMD's ROE of +0.13%. Regarding short-term risk, ENOV is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ENOV vs CSII Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas CSII's P/E ratio is -20.83. In terms of profitability, ENOV's ROE is -0.60%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ENOV is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check CSII's competition here
Bioventus Inc. (NASDAQ: BVS)
ENOV vs BVS Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, BVS has a market cap of 817M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while BVS trades at $12.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas BVS's P/E ratio is 16.08. In terms of profitability, ENOV's ROE is -0.60%, compared to BVS's ROE of +0.16%. Regarding short-term risk, ENOV is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check BVS's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ENOV vs SIBN Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, SIBN has a market cap of 770.8M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while SIBN trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas SIBN's P/E ratio is -44.56. In terms of profitability, ENOV's ROE is -0.60%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, ENOV is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SIBN's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ENOV vs SSII Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, SSII has a market cap of 742.5M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while SSII trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas SSII's P/E ratio is -72.36. In terms of profitability, ENOV's ROE is -0.60%, compared to SSII's ROE of -0.23%. Regarding short-term risk, ENOV is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SSII's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ENOV vs CBLL Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, CBLL has a market cap of 710.3M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while CBLL trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas CBLL's P/E ratio is -11.48. In terms of profitability, ENOV's ROE is -0.60%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, ENOV is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check CBLL's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ENOV vs TCMD Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, TCMD has a market cap of 648.3M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while TCMD trades at $28.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas TCMD's P/E ratio is 32.66. In terms of profitability, ENOV's ROE is -0.60%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check TCMD's competition here
Cerus Corporation (NASDAQ: CERS)
ENOV vs CERS Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, CERS has a market cap of 627.2M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while CERS trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas CERS's P/E ratio is -62.48. In terms of profitability, ENOV's ROE is -0.60%, compared to CERS's ROE of -0.15%. Regarding short-term risk, ENOV is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check CERS's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
ENOV vs BWAY Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, BWAY has a market cap of 617M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while BWAY trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas BWAY's P/E ratio is 39.96. In terms of profitability, ENOV's ROE is -0.60%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, ENOV is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check BWAY's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ENOV vs SRDX Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ENOV's ROE is -0.60%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ENOV is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ENOV vs CTKB Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, CTKB has a market cap of 596.6M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while CTKB trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas CTKB's P/E ratio is -35.54. In terms of profitability, ENOV's ROE is -0.60%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, ENOV is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check CTKB's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ENOV vs APEN Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas APEN's P/E ratio is -9.43. In terms of profitability, ENOV's ROE is -0.60%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ENOV is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check APEN's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ENOV vs NPCE Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, NPCE has a market cap of 548.2M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while NPCE trades at $16.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas NPCE's P/E ratio is -27.72. In terms of profitability, ENOV's ROE is -0.60%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, ENOV is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check NPCE's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ENOV vs ZIMV Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ENOV's ROE is -0.60%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, ENOV is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ZIMV's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ENOV vs KIDS Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, KIDS has a market cap of 493.5M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while KIDS trades at $19.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas KIDS's P/E ratio is -18.66. In terms of profitability, ENOV's ROE is -0.60%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, ENOV is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check KIDS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ENOV vs OFIX Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, OFIX has a market cap of 468.1M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while OFIX trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas OFIX's P/E ratio is -47.17. In terms of profitability, ENOV's ROE is -0.60%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, ENOV is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check OFIX's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ENOV vs CLPT Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, CLPT has a market cap of 454.3M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while CLPT trades at $15.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas CLPT's P/E ratio is -15.00. In terms of profitability, ENOV's ROE is -0.60%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, ENOV is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check CLPT's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ENOV vs PACB Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, PACB has a market cap of 447.3M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while PACB trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas PACB's P/E ratio is -2.94. In terms of profitability, ENOV's ROE is -0.60%, compared to PACB's ROE of -4.88%. Regarding short-term risk, ENOV is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check PACB's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ENOV vs VREX Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, VREX has a market cap of 444.2M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while VREX trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas VREX's P/E ratio is 11.11. In terms of profitability, ENOV's ROE is -0.60%, compared to VREX's ROE of -0.18%. Regarding short-term risk, ENOV is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check VREX's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ENOV vs DCTH Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, DCTH has a market cap of 442.2M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while DCTH trades at $12.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas DCTH's P/E ratio is 1281.00. In terms of profitability, ENOV's ROE is -0.60%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, ENOV is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check DCTH's competition here
Electromed, Inc. (AMEX: ELMD)
ENOV vs ELMD Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ELMD has a market cap of 348.8M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ELMD trades at $42.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ELMD's P/E ratio is 36.00. In terms of profitability, ENOV's ROE is -0.60%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, ENOV is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ELMD's competition here
Carlsmed, Inc. (NASDAQ: CARL)
ENOV vs CARL Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, CARL has a market cap of 317M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while CARL trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas CARL's P/E ratio is -4.65. In terms of profitability, ENOV's ROE is -0.60%, compared to CARL's ROE of -0.62%. Regarding short-term risk, ENOV is more volatile compared to CARL. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check CARL's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ENOV vs AVR Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, AVR has a market cap of 310.9M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while AVR trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas AVR's P/E ratio is -3.79. In terms of profitability, ENOV's ROE is -0.60%, compared to AVR's ROE of -1.24%. Regarding short-term risk, ENOV is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check AVR's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ENOV vs SMLR Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ENOV's ROE is -0.60%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, ENOV is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ENOV vs TMCI Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, TMCI has a market cap of 279M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while TMCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas TMCI's P/E ratio is -4.57. In terms of profitability, ENOV's ROE is -0.60%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, ENOV is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check TMCI's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ENOV vs SGHT Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, SGHT has a market cap of 273.7M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while SGHT trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas SGHT's P/E ratio is -7.08. In terms of profitability, ENOV's ROE is -0.60%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, ENOV is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SGHT's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ENOV vs MGRM Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ENOV's ROE is -0.60%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, ENOV is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check MGRM's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ENOV vs CATX Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, CATX has a market cap of 230.7M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while CATX trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas CATX's P/E ratio is -2.12. In terms of profitability, ENOV's ROE is -0.60%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ENOV is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check CATX's competition here
RxSight, Inc. (NASDAQ: RXST)
ENOV vs RXST Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, RXST has a market cap of 229.8M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while RXST trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas RXST's P/E ratio is -7.71. In terms of profitability, ENOV's ROE is -0.60%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ENOV is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check RXST's competition here
Nevro Corp. (NYSE: NVRO)
ENOV vs NVRO Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ENOV's ROE is -0.60%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ENOV is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check NVRO's competition here
Picard Medical, Inc. (AMEX: PMI)
ENOV vs PMI Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, PMI has a market cap of 220.4M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while PMI trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas PMI's P/E ratio is -0.12. In terms of profitability, ENOV's ROE is -0.60%, compared to PMI's ROE of +4.99%. Regarding short-term risk, ENOV is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check PMI's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ENOV vs SENS Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, SENS has a market cap of 213.6M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while SENS trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas SENS's P/E ratio is -2.56. In terms of profitability, ENOV's ROE is -0.60%, compared to SENS's ROE of -1.30%. Regarding short-term risk, ENOV is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check SENS's competition here
Profound Medical Corp. (NASDAQ: PROF)
ENOV vs PROF Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, PROF has a market cap of 207.3M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while PROF trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas PROF's P/E ratio is -5.52. In terms of profitability, ENOV's ROE is -0.60%, compared to PROF's ROE of -0.70%. Regarding short-term risk, ENOV is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check PROF's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ENOV vs FOCL Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, FOCL has a market cap of 203.7M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while FOCL trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas FOCL's P/E ratio is -6.99. In terms of profitability, ENOV's ROE is -0.60%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, ENOV is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check FOCL's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
ENOV vs ANIK Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ANIK has a market cap of 202.9M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ANIK trades at $15.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ANIK's P/E ratio is 31.12. In terms of profitability, ENOV's ROE is -0.60%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, ENOV is more volatile compared to ANIK. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ANIK's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ENOV vs BSGM Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ENOV's ROE is -0.60%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, ENOV is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check BSGM's competition here
Quanterix Corporation (NASDAQ: QTRX)
ENOV vs QTRX Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, QTRX has a market cap of 182.1M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while QTRX trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas QTRX's P/E ratio is -2.42. In terms of profitability, ENOV's ROE is -0.60%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, ENOV is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check QTRX's competition here
Inogen, Inc. (NASDAQ: INGN)
ENOV vs INGN Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, INGN has a market cap of 180.3M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while INGN trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas INGN's P/E ratio is -7.32. In terms of profitability, ENOV's ROE is -0.60%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ENOV is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check INGN's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ENOV vs MDGS Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ENOV's ROE is -0.60%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ENOV is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check MDGS's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ENOV vs TLSI Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, TLSI has a market cap of 162.6M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while TLSI trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas TLSI's P/E ratio is -2.55. In terms of profitability, ENOV's ROE is -0.60%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, ENOV is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check TLSI's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ENOV vs QIPT Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ENOV's ROE is -0.60%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ENOV is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check QIPT's competition here
CVRx, Inc. (NASDAQ: CVRX)
ENOV vs CVRX Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, CVRX has a market cap of 130.3M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while CVRX trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas CVRX's P/E ratio is -2.43. In terms of profitability, ENOV's ROE is -0.60%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, ENOV is less volatile compared to CVRX. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check CVRX's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ENOV vs RCEL Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, RCEL has a market cap of 126.7M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while RCEL trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas RCEL's P/E ratio is -3.25. In terms of profitability, ENOV's ROE is -0.60%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, ENOV is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check RCEL's competition here
iCAD, Inc. (NASDAQ: ICAD)
ENOV vs ICAD Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ENOV's ROE is -0.60%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ENOV is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ICAD's competition here
Owlet, Inc. (NYSE: OWLT)
ENOV vs OWLT Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, OWLT has a market cap of 101.1M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while OWLT trades at $5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas OWLT's P/E ratio is -39.93. In terms of profitability, ENOV's ROE is -0.60%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, ENOV is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check OWLT's competition here
Solana Company (NASDAQ: HSDT)
ENOV vs HSDT Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, HSDT has a market cap of 99.8M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while HSDT trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas HSDT's P/E ratio is -0.02. In terms of profitability, ENOV's ROE is -0.60%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, ENOV is more volatile compared to HSDT. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check HSDT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
ENOV vs HJLI Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas HJLI's P/E ratio is N/A. In terms of profitability, ENOV's ROE is -0.60%, compared to HJLI's ROE of -0.66%. Regarding short-term risk, ENOV is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check HJLI's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
ENOV vs LUCD Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, LUCD has a market cap of 97.2M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while LUCD trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas LUCD's P/E ratio is -2.57. In terms of profitability, ENOV's ROE is -0.60%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, ENOV is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for ENOV.Check LUCD's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
ENOV vs ASXC Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas ASXC's P/E ratio is -1.12. In terms of profitability, ENOV's ROE is -0.60%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, ENOV is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check ASXC's competition here
Rapid Micro Biosystems, Inc. (NASDAQ: RPID)
ENOV vs RPID Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, RPID has a market cap of 93.8M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while RPID trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas RPID's P/E ratio is -1.85. In terms of profitability, ENOV's ROE is -0.60%, compared to RPID's ROE of -1.32%. Regarding short-term risk, ENOV is more volatile compared to RPID. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check RPID's competition here
QT Imaging Holdings, Inc. (NASDAQ: QTI)
ENOV vs QTI Comparison July 2026
Enovis Corporation (NYSE: ENOV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.6B. In comparison, QTI has a market cap of 89M. Regarding current trading prices, ENOV is priced at $27.07 on the NYSE, while QTI trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 8.01, whereas QTI's P/E ratio is -4.82. In terms of profitability, ENOV's ROE is -0.60%, compared to QTI's ROE of -63.31%. Regarding short-term risk, ENOV is more volatile compared to QTI. This indicates higher risk in terms of short-term price fluctuations for ENOV.Check QTI's competition here